SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Cyclacel Pharmaceuticals Q1 EPS $(2.770) Beats $(2.900) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.770) per share which beat the analyst consensus estimate of $(2.900) by 4.48 percent. This is a 1878.57 percent decrease over losses of $(0.140) per

Benzinga · 05/12/2020 20:06

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.770) per share which beat the analyst consensus estimate of $(2.900) by 4.48 percent. This is a 1878.57 percent decrease over losses of $(0.140) per share from the same period last year.